Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (2013 - 2025)
Larimar Therapeutics (LRMR) posted Net Income towards Common Stockholders of -$65.5 million for Q4 2025, down 29.26% on a QoQ basis from -$50.7 million in Q3 2025, and up 67.93% year-over-year from -$39.0 million in Q4 2024.
Larimar Therapeutics (LRMR) Net Income towards Common Stockholders (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Net Income towards Common Stockholders history runs 13 years deep, the most recent figure standing at -$65.5 million for Q4 2025.
- Quarterly Net Income towards Common Stockholders rose 67.93% year-over-year to -$65.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$182.4 million (up 37.55% YoY) and the FY2025 annual result came in at -$174.0 million, up 34.07% from the prior year.
- Net Income towards Common Stockholders was -$65.5 million for Q4 2025 at Larimar Therapeutics, down from -$50.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$9.7 million in Q1 2023 and bottomed at -$204.3 million in Q4 2024.
- A 5-year average of -$52.6 million and a median of -$26.7 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 186.01% — and 2025, when it soared 67.93%.
- Larimar Therapeutics' Net Income towards Common Stockholders stood at -$133.1 million in 2021, then decreased by 6.14% to -$141.3 million in 2022, then retreated by 10.38% to -$155.9 million in 2023, then sank by 31.03% to -$204.3 million in 2024, then surged by 67.93% to -$65.5 million in 2025.
- Business Quant data shows LRMR's Net Income towards Common Stockholders at -$65.5 million in Q4 2025, -$50.7 million in Q3 2025, and -$29.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | -65.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.52 Mn |
| Sep 30, 2025 | -50.69 Mn |
| Jun 30, 2025 | -28.98 Mn |
| Mar 31, 2025 | -37.24 Mn |
| Dec 31, 2024 | -204.32 Mn |
| Sep 30, 2024 | -25.66 Mn |
| Jun 30, 2024 | -34.40 Mn |
| Mar 31, 2024 | -27.73 Mn |
| Dec 31, 2023 | -155.93 Mn |
| Sep 30, 2023 | -17.60 Mn |
| Jun 30, 2023 | -16.62 Mn |
| Mar 31, 2023 | -9.70 Mn |
| Dec 31, 2022 | -141.27 Mn |
| Sep 30, 2022 | -10.86 Mn |
| Jun 30, 2022 | -11.18 Mn |
| Mar 31, 2022 | -17.39 Mn |
| Dec 31, 2021 | -133.10 Mn |
| Sep 30, 2021 | -19.69 Mn |
| Jun 30, 2021 | -21.94 Mn |
| Mar 31, 2021 | -21.80 Mn |